Consensus Repligen Corporation Deutsche Boerse AG

Stocks

RGN

US7599161095

Medical Equipment, Supplies & Distribution

Market Closed - Deutsche Boerse AG 14:03:00 21/08/2026 HKT			5-day change	1st Jan Change
152.75 ^EUR	+2.17%		+6.30%	+9.77%

07-30	Tranche Update on Repligen Corporation's Equity Buyback Plan announced on June 18, 2008.	CI
07-30	Tranche Update on Repligen Corporation's Equity Buyback Plan announced on December 7, 2023.	CI

Evolution of the Average Target: Repligen Corporation

Evolution of the Target Price: Repligen Corporation

Changes in Analyst Recommendations: Repligen Corporation

e3.QUdsrI78_8jUr_sCwH7k0OmHQ8dHnYBJqyfk7LLIgI0.FwsEx96MkamW-JgwlROLspHdAP8Dy-M53FPRhoWq5ttyFjn-65elq6X6yw~39aed8f70c2ade9751eff905d2c7164e

Analysts' recommendations: Repligen Corporation

07-30	Repligen's Diversity of Growth Drivers Support Return to Mid-Teens Organic Sales Growth, RBC Says	MT
07-29	RBC Raises Price Target on Repligen to $185 From $160, Keeps Outperform Rating	MT
07-29	Deutsche Bank Adjusts Repligen Price Target to $200 From $180, Maintains Buy Rating	MT
07-07	Benchmark Upgrades Repligen to Buy From Hold, Price Target is $185	MT
05-16	Repligen Likely to Benefit From Diverse Growth Factors, RBC Says	MT
04-17	Rothschild & Co Redburn Initiates Repligen at Buy With $160 Price Target	MT
02-25	UBS Adjusts Price Target on Repligen to $195 From $200, Maintains Buy Rating	MT
01-16	UBS Adjusts Price Target on Repligen to $200 From $190, Maintains Buy Rating	MT
01/10/25	HSBC Initiates Repligen at Buy With $150 Price Target	MT
23/09/25	Repligen Shares Rise After Upgrade From Evercore ISI	MT
22/09/25	Evercore ISI Upgrades Repligen to Outperform From In Line, Price Target is $155	MT
03/09/25	RBC Lifts Price Target on Repligen to $205 From $204, Keeps Outperform Rating	MT
30/07/25	RBC Raises Price Target on Repligen to $204 From $193, Keeps Outperform Rating	MT
29/07/25	Life sciences firm Repligen beats Q2 revenue estimates, raises full-year guidance	RE
01/07/25	RBC Lifts Price Target on Repligen to $193 From $191, Keeps Outperform Rating	MT
24/06/25	Barclays Initiates Repligen at Overweight With $150 Price Target	MT
30/04/25	RBC Lowers Price Target on Repligen to $189 From $202, Keeps Outperform Rating	MT
30/04/25	Wolfe Research Upgrades Repligen to Outperform From Peerperform	MT
08/04/25	RBC Cuts Price Target on Repligen to $202 From $219, Keeps Outperform Rating	MT
18/03/25	Evercore ISI Initiates Repligen at In Line With $155 Price Target	MT
21/02/25	RBC Raises Price Target on Repligen to $205 From $203, Keeps Outperform Rating	MT
21/02/25	Deutsche Bank Adjusts Repligen Price Target to $195 From $190, Maintains Buy Rating	MT
10/02/25	TD Cowen Initiates Repligen at Buy With $200 Price Target	MT
04/02/25	RBC Trims Price Target on Repligen to $203 From $207, Keeps Outperform Rating	MT
09/12/24	RBC Lifts Price Target on Repligen to $207 From $205, Keeps Outperform Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ABBOTT LABORATORIES					+3.05%
	MEDTRONIC PLC					+5.45%
	CENCORA, INC.					+16.12%
	HOYA CORPORATION					+22.73%
	BECTON, DICKINSON AND COMPANY					+1.26%
	DEXCOM, INC.					+1.93%
	MEDLINE INC.					+30.23%
	WEST PHARMACEUTICAL SERVICES, INC.					+14.63%
	TERUMO CORPORATION					+21.96%
	Average					+13.04%
	Weighted average by Cap.					+8.94%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

181.13USD

Average target price

185.70USD

Spread / Average Target

+2.52%

High Price Target

220.00USD

Spread / Highest target

+21.46%

Low Price Target

145.00USD

Spread / Lowest Target

-19.95%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

RBC Capital Markets
Deutsche Bank Securities
Benchmark Company
Rothschild & Co Redburn
UBS
HSBC
Evercore ISI
Barclays
Wolfe Research
TD Cowen
Guggenheim
KeyBanc Capital Markets
Craig-Hallum
JPMorgan Chase
Stephens Inc.
Wells Fargo Securities
Stifel Nicolaus
SVB Securities LLC
SVB Leerink
Exane BNP Paribas
William O'Neil & Co
HC Wainwright